12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Soliris eculizumab: Phase II data

An investigator-initiated, single-arm, open-label, U.S. Phase II trial in 14 women with severe, relapsing neuromyelitis optica showed that Soliris significantly reduced the median annualized attack rate, the primary endpoint, from 3 attacks/patient pre-treatment to 0 attacks/patient after 12 months of treatment (p<0.0001). At 12 months, 12 patients were completely attack-free, while the other 2 patients had single possible relapses as reported by investigators - 1 patient had back pain without clinical or radiological evidence of inflammation of the spinal cord, while the other patient had new onset of visual blurring with...

Read the full 433 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >